Farxiga (Dapagliflozin) and Anesthesia: What Every Woman Needs to Know Before Surgery

Why Farxiga and Anesthesia Are a High-Risk Combination

The interaction between dapagliflozin and anesthesia is not a minor scheduling inconvenience. It is a recognized patient-safety emergency waiting to happen if the drug is not stopped in time. Anesthesia, surgical stress, fasting, and intravenous fluid shifts all conspire to trigger a specific and dangerous syndrome called euglycemic diabetic ketoacidosis (euDKA).

What Euglycemic DKA Actually Means

Standard diabetic ketoacidosis (DKA) announces itself with very high blood glucose, often above 250 mg/dL. Euglycemic DKA, the perioperative variant associated with SGLT2 inhibitors like dapagliflozin, is more deceptive. Blood glucose can remain below 200 mg/dL, or even in the normal range, while ketones accumulate to dangerous levels in the blood and urine. A 2016 FDA Drug Safety Communication confirmed this risk class-wide for SGLT2 inhibitors, including dapagliflozin.

The normal-looking glucose reading is exactly what makes perioperative euDKA so dangerous in the operating room. A nurse or anesthesiologist checking blood glucose may not flag a problem. Meanwhile, ketoacidosis advances.

The Mechanism: How Dapagliflozin Sets the Stage

Dapagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) in the kidney, forcing roughly 70 grams of glucose per day into the urine rather than back into the bloodstream. The approved Farxiga prescribing information confirms this glucose-lowering mechanism. When you add surgical fasting (nothing by mouth for 8 or more hours), the body shifts rapidly toward fat oxidation and ketone production. The SGLT2 blockade raises glucagon levels relative to insulin, pushing the liver further toward ketogenesis. Anesthetic agents independently suppress insulin secretion and increase counter-regulatory hormones like cortisol and epinephrine, compounding the ketone load. The result: a biochemical perfect storm.

How Common Is Perioperative euDKA?

Precise incidence data specific to women are limited, reflecting the broader evidence gap in sex-disaggregated perioperative research. Pooled case series suggest perioperative euDKA occurs in roughly 0.6 to 2.0 percent of SGLT2 inhibitor users undergoing major surgery, though this figure is almost certainly an underestimate because the condition is frequently misdiagnosed in the immediate postoperative period. A 2019 analysis in Diabetes Care found that delays in diagnosis of perioperative euDKA significantly worsened outcomes, including prolonged ICU stays and a small number of deaths.

The 3-Day Rule: When to Stop Farxiga Before Surgery

Most major anesthesia and diabetes guidelines now converge on a minimum of 3 days (72 hours) of Farxiga cessation before elective procedures requiring general, regional, or neuraxial anesthesia.

What the Guidelines Say

The American Diabetes Association 2024 Standards of Care recommend holding SGLT2 inhibitors at least 3 to 4 days before elective surgery. The Society for Ambulatory Anesthesia (SAMBA) consensus statement aligns with this window and extends the recommendation to any procedure requiring a fasting state of more than 4 hours, including colonoscopies and endoscopies performed under sedation.

For emergency surgery, the calculus is different. If you arrive for an unplanned operation and have taken Farxiga within the preceding 3 days, your anesthesia team should measure blood and urine ketones before induction and monitor ketones intraoperatively. Glucose monitoring alone is insufficient.

Procedures That Require the 3-Day Hold

• General anesthesia (any duration)
• Spinal or epidural (neuraxial) anesthesia
• Deep sedation (propofol-based MAC anesthesia)
• Any procedure requiring an NPO (nothing by mouth) period of more than 4 hours
• Colonoscopy with bowel prep (the prep itself shifts fluid and electrolytes)

Minor procedures under local anesthesia only, where you eat normally before and after, may not require the hold. Confirm this with both your prescribing clinician and your procedural team.

What to Tell Your Surgical Team

Do not assume your surgeon, anesthesiologist, or pre-op nurse has already reviewed your medication list for SGLT2 inhibitors. Medication reconciliation errors are common. Specifically say: "I take dapagliflozin, brand name Farxiga. I need ketone monitoring if I have taken it within the past 3 days." Bring the bottle. Write it down.

Women-Specific Risks: PCOS, Hormonal Cycles, and Metabolic Differences

Women taking Farxiga face a distinct set of perioperative considerations that male-default clinical guidelines frequently underaddress. Three areas stand out.

PCOS and Off-Label Farxiga Use

Dapagliflozin is being used off-label in women with polycystic ovary syndrome (PCOS) to address insulin resistance, weight, and cardiometabolic risk factors. PCOS affects 8 to 13 percent of women of reproductive age globally. These women often have a background state of mildly elevated ketones due to metabolic dysregulation, even without diabetes. The 3-day perioperative hold applies to this group with equal force, though the off-label nature of the prescription means it may not appear in standard surgical medication review checklists. If you take Farxiga for PCOS and you are scheduled for surgery, explicitly flag both the drug and the indication to your anesthesia team.

Menstrual Cycle Timing and Perioperative Metabolism

Estrogen and progesterone fluctuations across the menstrual cycle alter insulin sensitivity. In the luteal phase, progesterone promotes mild insulin resistance, which theoretically increases ketone production during fasting. No prospective trial has examined whether luteal-phase surgery on SGLT2 inhibitors raises euDKA risk above that seen in the follicular phase. This is a genuine evidence gap. Out of caution, if you have flexibility in scheduling an elective procedure, scheduling it in the early follicular phase (days 2 to 7 of your cycle) and confirming a full 3-day hold on Farxiga is the most conservative approach.

Perimenopause and Menopause

Women in perimenopause taking Farxiga for heart failure with reduced ejection fraction or chronic kidney disease may also use it during a period when estrogen withdrawal independently worsens insulin sensitivity. A 2023 paper in Menopause journal reported that insulin resistance worsens in perimenopause independent of weight gain, which could amplify fasting-related ketosis during the perioperative window. Menopausal women on Farxiga should follow the same 3-day hold protocol and should inform their anesthesiologist of their hormonal status if they are also on systemic hormone therapy, as some anesthetic protocols vary in this context.

Alcohol and Farxiga: A Separate but Related Risk

Can you drink on Farxiga? Short answer: alcohol is not recommended, and it becomes particularly dangerous if you are approaching a surgical date.

Alcohol accelerates ketone production through its own metabolic pathway. Ethanol metabolism generates NADH, which shifts hepatic metabolism away from glucose production and toward ketogenesis. When combined with the SGLT2-mediated state of relative glucagon excess that dapagliflozin creates, even moderate alcohol intake can push ketone levels higher than expected. A pharmacokinetic note in the Farxiga label does not list alcohol as a formal contraindication, but the mechanistic interaction is well-established.

In the perioperative context specifically, any alcohol consumed in the 48 hours before surgery adds to the ketone burden you are already carrying if you have taken Farxiga recently. The practical guidance: no alcohol for at least 48 hours before surgery, and no alcohol if you suspect you are developing ketoacidosis at any point while on Farxiga.

Outside the perioperative window, occasional moderate alcohol (one standard drink per day for women per CDC guidance) does not produce a formal contraindication with dapagliflozin, but the additive ketone risk is real.

Pregnancy, Lactation, and Contraception: Required Safety Information

Farxiga is contraindicated in the second and third trimesters of pregnancy. This is not a soft caution. It is a labeling contraindication.

Pregnancy Risk

Animal studies showed dapagliflozin caused adverse fetal renal effects during the period of kidney development, which in humans corresponds to the second and third trimesters. The FDA-approved prescribing information assigns this risk with a clear warning to discontinue Farxiga as soon as pregnancy is detected after the first trimester. Human data are limited to case reports and pharmacovigilance databases, not adequately powered prospective studies. This is a documented evidence gap. Women of reproductive age on Farxiga should use reliable contraception, and pregnancy testing before any elective surgical procedure is standard pre-op care.

If you are planning to conceive, discuss stopping Farxiga with your prescribing clinician well in advance. For women using Farxiga off-label for PCOS, this conversation is particularly relevant because PCOS itself is a leading cause of infertility, and surgical procedures like laparoscopic ovarian drilling or hysteroscopy may come up in the fertility workup.

First Trimester

Data in the first trimester in humans are sparse. Some observational data from pregnancy registries suggest no clear teratogenic signal in early pregnancy, but the sample sizes are too small to draw firm conclusions. ACOG does not endorse SGLT2 inhibitor use in pregnancy and recommends switching to insulin for glucose management during pregnancy.

Lactation

Dapagliflozin is present in rat milk. Human lactation transfer data are not available. Because of the potential for serious adverse effects in a nursing infant, including effects on renal development, Farxiga is not recommended during breastfeeding. Women who are postpartum and breastfeeding should discuss alternative agents with their clinician before resuming dapagliflozin.

Contraception Requirement

Any woman of reproductive age who continues Farxiga should use effective contraception. This is especially relevant in women with PCOS, many of whom have irregular cycles that make natural cycle tracking unreliable for pregnancy avoidance.

Recognizing Perioperative euDKA: Symptoms Every Woman Should Know

Recovery room nurses and post-surgical wards may not think to check ketones in a patient who looks unwell after surgery, particularly if glucose readings are normal. Knowing the warning signs yourself, and communicating them to whoever is at your bedside, could be critical.

Symptoms to Report Immediately After Surgery

• Nausea or vomiting that does not resolve with standard antiemetics
• Abdominal pain without an obvious surgical explanation
• Breathing that feels labored or faster than normal (Kussmaul respirations)
• Confusion or unusual mental fogginess beyond expected anesthesia recovery
• A fruity or acetone-like breath odor

These symptoms in the context of recent Farxiga use should prompt urgent blood gas analysis and a serum or urine ketone check, not just a fingerstick glucose.

How euDKA Is Treated

Treatment involves insulin infusion to suppress ketogenesis, intravenous dextrose to prevent hypoglycemia during insulin administration, fluid resuscitation, and electrolyte correction. The 2019 Diabetes Care paper describes a median resolution time of roughly 18 to 24 hours with appropriate treatment. Dapagliflozin should not be restarted until euDKA has fully resolved and oral intake has been established.

When to Restart Farxiga After Surgery

Restarting too soon is a separate risk. The general principle from the ADA 2024 Standards of Care is to resume SGLT2 inhibitors only when the patient is medically stable, eating and drinking normally, and the surgical team has given explicit clearance. In practice this means at least 24 to 48 hours after a procedure under general anesthesia, and longer for major abdominal surgery where oral intake may be delayed for days.

Do not restart based on your own judgment. The restart decision should come from your prescribing clinician in coordination with your surgeon, with ketone levels confirmed as normal if there is any uncertainty.

Who This Applies to and Who It Does Not

Women Who Take Farxiga and Must Follow the Perioperative Protocol

• Women with type 2 diabetes on Farxiga 10 mg daily
• Women with heart failure with reduced ejection fraction on Farxiga 10 mg daily
• Women with chronic kidney disease (CKD stage 3b to 4) on Farxiga 10 mg daily
• Women using Farxiga off-label for PCOS or metabolic syndrome
• Any woman on a combination pill that contains dapagliflozin (Qtern, Xigduo XR)

Situations Where the Risk Is Lower but Vigilance Is Still Needed

• Minor outpatient procedures under local anesthesia only, where full oral intake continues
• Diagnostic imaging with contrast where no fasting longer than 4 hours is required

Even in lower-risk situations, inform your procedural team about Farxiga. Some contrast agents used in imaging have their own metabolic interactions, and your full medication list should always be disclosed.

Other Farxiga Drug Interactions Worth Knowing

The anesthesia interaction is the most urgent, but dapagliflozin has other clinically meaningful interactions that affect women specifically.

Diuretics (furosemide, hydrochlorothiazide): Dapagliflozin has a diuretic effect of its own. Combining it with another diuretic increases the risk of dehydration, orthostatic hypotension, and electrolyte imbalance. Women in perimenopause already have higher rates of orthostatic symptoms due to autonomic changes from estrogen decline. The Farxiga label includes this as a precaution.

Insulin and insulin secretagogues (sulfonylureas): Combining dapagliflozin with insulin or a sulfonylurea increases hypoglycemia risk. This combination is common in type 2 diabetes management. Dose adjustment of the insulin or sulfonylurea is often needed. The DECLARE-TIMI 58 trial, which enrolled 17,160 participants with type 2 diabetes including a meaningful proportion of women, confirmed dapagliflozin's cardiovascular benefits but also documented hypoglycemia events when combined with secretagogues.

Lithium: Dapagliflozin can lower lithium levels modestly through increased renal clearance. Women with bipolar disorder on lithium who are prescribed Farxiga should have lithium levels monitored after starting or stopping dapagliflozin.

A Note on the Evidence Gap for Women

Women were included in the major dapagliflozin trials (DECLARE-TIMI 58, DAPA-HF, DAPA-CKD) but sex-disaggregated perioperative safety data are not published in usable form. DAPA-HF enrolled approximately 23 percent women, which is better than earlier cardiovascular trials but still means the majority of safety data come from men. No published trial has specifically examined perioperative euDKA rates in women versus men on SGLT2 inhibitors, or assessed whether hormonal fluctuations across the menstrual cycle or menopausal transition modify the risk. The guidance in this article is extrapolated from mixed-sex trial data and case series, not from women-specific perioperative studies. This gap is real, and it matters.

As WomanRx clinical reviewer Dr. Elena Vasquez, MD, puts it: "My pre-op checklist for any woman on Farxiga now starts with confirming the 3-day hold happened. The euglycemic presentation means a normal glucose reading in recovery gives false reassurance. We train staff to check ketones, not just glucose, and to take the patient's own report of nausea or breathlessness seriously even when the numbers look fine."